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ABSTRACT
Background: Takokak fruit (Solanum torvum) is a type of eggplant containing solasodin,
solamargin, solasonin and other phytochemicals components with anti-inflammatory and anti-
cancer properties. The purpose of this study was to examine the effects of takokak ethanol
extract on TNF-α, IL6, and SOD levels.
Methods: Experimental factorial study design, with the effect of takokak extract
concentration factor (0, 400 and 800 mg/kgBW), takokak extract administration time factor
including preventive (weeks 1-7) and curative (weeks 6-12) administration, and necropsy
factor (necropsy in weeks 12 and 16). The data obtained included rats body weight, TNF-α,
IL-6 and SOD levels.
Results: The result showed that the interaction between takokak concentration and handling
has significant effect on the increase of TNF-α levels (p=0.003) and the decrease of IL-6
levels (p=0.000). Interaction between takokak concentration, handling and necropsy has
significant effect on the increase of SOD levels (p=0.010).
Conclusion: Takokak ethanol extract has significant effect on the increase of TNF-α, and
SOD levels, and the decrease of IL-6 levels.
Keywords: Takokak (Solanum torvum), inflammation
INTRODUCTION
Carcinogenesis is a multistage process involving
molecules and cells with three distinct stages: initiation,
promotion and progression. Initiation is a quick and
irreversible process with intracellular and extracellular
binding. Carcinogen exposure will occur in the early
stage, and it will be distributed and transported to the
tissues and organs. Metabolism and detoxification will
be activated and reactive species will form a covalent
bond with the deoxyribonucleic acid (DNA) of the
target cells, all of which will cause genetic damage. To
the contrary, tumor promotion is a long and reversible
process resulting in the activation of proliferation,
which is an accumulation of pre-neoplastic cells.
Progression is the final stage of neoplastic
transformation with invasive and metastatic tumor
growth.1
The relationship between inflammation and cancer
has been demonstrated by epidemiology and clinical
studies. For example, inflammation is associated with
10 times higher risk of developing colorectal cancer.
Anti-inflammation can reduce the incidence of colon
cancer. The causes of inflammation are microbial
infections, or non-infectious causes such as mechanical
and chemical irritation. Chronic inflammation caused by
infection may contribute to the carcinogenesis.
Inflammation can increase the risk for pharyngeal
cancer, pancreatic cancer, and gallbladder cancer.2
Chemical carcinogen such as 7,12-
dimethylbenz(a)anthracene (DMBA) will bind to the
DNA, which is likely to induce tumor. Several
chemopreventive agents can bind to DMBA that may
cause tumor, by reducing the binding of DMBA to
DNA. Cell proliferation is very important in the
regulation of carcinogens that may cause cancer.3
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exposure to environmental carcinogens may contribute
to cancer risk in humans. Rats are often used as models
for human cancer because of their similarities in terms
of pathology, cellular authenticity and hormone
dependency.4 Oxidative stress caused by oxidants can
lead to several diseases such as cancer. The high
production of ROS (Reactive Oxygen Species) causing
oxidative damage to DNA will further contribute to the
mutagenesis and carcinogenesis.5 Inflammation in the
cellular environment may increase mutation rates.
Inflammation is activated by ROS and RNS, which can
induce DNA damage and gene instability.
Natural ingredients (herbal medicine) had
contributed to the development of modern medicine.
Herbal medicine from natural ingredients can regulate
several inflammatory mediators such as the metabolism
of arachidonic acid, peptide, cytokine, and excitatory
amino acid, production of second messengers (cGMP,
cAMP, protein kinases, and calcium), expression of
transcription factors (AP-1, NF-kB) and proto-oncogene
(c-jun, cfos and c-myc), and expression of
proinflammatory molecules such as inducible NO
synthase (iNOS), cyclooxygenase (COX-2), cytokine
(IL-1β, TNF-α), neuropeptide and protease.6
A study by Amir and Kumar7 showed that crude
steroidal glycoalcaloids extract Solanum ligustrinum has
anti-inflammatory properties in rabbits and guinea pigs.
Several components of this substance are scopoletin and
B sitosterol-3-o-B-D-glucoside acyl extract from
dichloromethane. Another eggplant variant Solanum
nigrum can be used as anti-inflammation for several
diseases such as: liver, spleen, stomach, gut, and uterine
diseases, and inflammation of the esophagus and larynx.
Solanum nigrum alcohol extract can prevent edema in
albino rats. The anti-inflammation substance is
presumed to be glycoalcaloid steroid and genin steroid.
Several plants known as chemopreventive
substances may exert their anti-carcinogenic effect by
inhibiting cellular proliferation and inducing cell
differentiation and apoptosis. Medicinal herbs are rich
in antioxidants as anti-proliferation substances, and may
induce apoptosis.4 Takokak fruit (Solanum torvum) has
solasodin, solamargin, solasonin and other
phytochemicals components with anti-inflammatory and
anti-cancer properties. Based on the previous
explanations, a study will be conducted to determine the
anti-proliferation and anti-inflammation potential of
takokak for cancer cells in animal models. The purpose
of this study was to examine the effects of takokak
ethanol extract on TNF-α levels, IL6 levels, SOD levels,
and cancer cells proliferation.
METHOD
This is an in vivo experimental study with factorial
design on rats. The study treatments are takokak extract
concentrations of 0 mg/kg BW, 400 mg/kg BW and 800
mg/kg BW. The handlings are preventive takokak
extract administration by giving takokak extract in
conjunction with DMBA, and curative administration
by giving takokak extract after DMBA. Necropsy will
be performed at weeks 12 and 16. The study was
conducted in the Laboratory of Physiology Brawijaya
University Malang.
Tools and Materials
The materials used are DMBA from sigma and
takokak fruits from toga garden of Gunung Leutik
village Ciampea Bogor. The rats used are 40 days old
female Sprague-Dawley rats, purchased in the
Integrated Research and Testing Laboratory (LPPT)
Gajah Mada University Yogyakarta. Other chemicals
used in this study are anti-human IL-6, primary and
secondary IgG antibody, xanthine reagent, xanthine
oxidase, TCA, NaThio, mineral mix from the
Agricultural Products Technology of Bogor Agricultural
University, and 96% ethanol from Makmur Sejati store
Malang. The types of fodders used for animal models
feeding are corn, soybean, fishmeal, peanut, wheat
flour, bone meal, salt, cooking oil and vitamin B
complex from Malang local market. The tools used
include rotary evaporator, vacuum pump, shaker, oven
drying, elisa Hermle Labortechnik GMBH, vortek velp
scientifika, shaker-mixer vina instruments and electron
microscope.
Research Stages
Takokak Extraction
The takokak fruit was dried at 50oC for 9 days using
the oven. Next the takokak powder will be macerated
using 96% alcohol 1:7 for 24 hours. The extract fluid
was evaporated until a thick extract remains. Afterwards
the extract is stored at low temperatures until used in the
following studies.
Fodder making
Rats fodder is made from corn, roasted fish, peanut
roaster, soybean roaster, roasted bone, wheat flour,
mineral mix and vitamin B complex, each materials was
finely ground.8 The composition of rats fodder
consisting of; cornstarch (70%), fish meal (5%), bone
meal (1,5%), soybean flour (10%), peanut flour (5%),
mineral mix (0.2%), vitamin B complex (1 tablet/kg),
cooking oil (1%) and salt (0.2%). The fodder was mixed
and made every 10 days.
Animal Models
Each rat was placed in a plastic box with husks
covered floor, with room air humidity of about 50-60%
and room temperature of ±25oC, standard ration was
given to all white rats during adaptation and treatment
period. During adaptation period the rats were given
standard ration and drinks ad libitum. Rats’ body
weights were observed at week 0, 1, 2, and 3 and so
forth up to week 16. Fodder consumption was observed
everyday by weighing the residual fodder. Minimum
number of rats for each treatment is two, which was
calculated from the formula ((t-1)(r-1)> 15. This study
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had been approved by the Research Ethic Committee of
the Polytechnic of Health Malang Reg. no. 163/2012.
Diet and Treatments for The Animal Models
A total of 36 rats were divided into 6 groups, each
groups consisting of 6 rats. The rats were adapted for 10
days. Afterwards the rationing was varied based on the
treatment type. DMBA was given 20 mg/kg/BW orally
2 times per week for 5 weeks in 0,5 ml corn oil9. Rat
necropsy will be performed on weeks 12 and 16, 3 rats
each, and then the TNF-α levels, IL-6 levels and SOD
levels were analyzed. Anesthesia was performed by
ketamil injection 0.1 ml/rat (10 mg in 50 ml) or 0.02
mg/rat. About 2.5 ml of blood was taken from the heart
using 5 ml syringe.
The treatment was given as follows:
1. Group I, DMBA (positive control)
2. Group II, DMBA and takokak extract 400
mg/kgBW 1x/day from weeks 1-7.
3. Group III, DMBA and takokak extract 800
mg/kgBW 1x/day from weeks 1-7.
4. Group IV, DMBA (positive control)
5. Group V, DMBA and takokak extract 400
mg/kgBW 1x/day from weeks 6-12.
6. Group VI, DMBA and takokak extract 800
mg/kgBW 1x/day from weeks 6-12.
TNF-α Levels
Coating antigen is washed in micro tube plate by
mixing serum with 50 µl coating buffer at a 1:20 ratio,
and incubated for 1 night at 4°C. Then it was washed
with 50 µl 0.2% PBS tween 3 times for 3 minutes each.
Next blocking buffer (1% BSA in PBS) was added.
Then it was incubated at room temperature for 30
minutes. Subsequently it was washed with 50 µl 0.2%
PBS tween 3 times for 3 minutes each. Primary
antibody coating was added using primary antibody and
PBS at a 1:500 ratio, and then incubated for 2 hours at
room temperature. Then it was washed with 50 µl 0.2%
PBS tween 3 times for 3 minutes each. Secondary
antibody coating was added using conjugated AP
(Alkaline Phosphatase) IgG antibody and PBS at a
1:1000 ratio, and then incubated for 1 hour at room
temperature. Subsequently it was washed with 50 µl
0.2% PBS tween 3 times for 3 minutes each. SA-HRP at
a 1:1000 ratio was added and then incubated for 1 hour
at room temperature, and washed using 50 µl 0.2% PBS
tween 3 times for 3 minutes each. Sure blue TMB
(tetramethylbenzidine) was added, and then incubated
for 30 minutes at room temperature or in the dark. The
reaction was terminated by adding 1N HCl, and then it
was incubated for 15 minutes. Subsequently it was
analyzed using elisa at a 450 nm wavelength.10
IL-6 Levels
Coating buffer at a 1:4000 ratio was added to the
serum, and allowed to stand overnight at 4°C. It was
then washed using PBS tween for 6 times. Pure feel
anti-human IL-6 diluted in assay buffer at a 1:4000 ratio
was added. Subsequently it was incubated at room
temperature for 2 hours while shaken. It was then
washed using PBS tween for 6 times and 100 µl biotin
gout anti-human IgG at 1:800 ratio in assay buffer was
added. Subsequently it was incubated at room
temperature for 60 minutes while shaken. It was then
washed using PBS tween for 6 times and 100 μl SAHRP
at 1:500 ratio in 0.5 µl/2ml assay buffer was added.
Next it was washed using PBS tween for 6 times and
100 µl TMB substrate was added. Subsequently it was
incubated at room temperature for 10 minutes while
shaken, and 100 µl stop solution was added, then
analyzed using elisa at 450 nm wavelength.11
SOD Levels
Blood was centrifuged at 3000 rpm for 10 minutes
and the serum was collected. Serum was centrifuged at
6000 rpm for 10 minutes, and the supernatant was
collected. Sample volumes of 100 μl were taken and
100 µl of xanthine, xanthine oxidase, NBT, PBS reagent
were added respectively, next PBS was added to the
final volume of 1000 µl, incubated at 30°C for 30
minutes, and then analyzed using elisa at 580 nm
wavelength.12
Data analysis
Data was presented using descriptive statistics and
analysis of variance. The study had been approved by
the Research Ethic Committee of the Polytechnic of
Health Malang.
RESULT
Body Weight
The range of body weight for the rats in this study is
between 122.5 g to 256.0 g. The mean body weight of
rats is 195.7 g. The mean body weight is 175.6 g for
preventive treatment (during takokak administration)
and 163.3 g for curative treatment.
Analysis of variance showed that the interaction
between takokak concentration and increased
concentration and preventive or curative treatment have
a significant effect on body weight (p=0.022), increased
takokak concentration and preventive or curative
treatments were found to play a role in weight gain.
Body weight of rats from preventive group is presented
in Figure 1 and body weight of rats from curative group
is presented in Figure 2.
TNF-α Levels
The range of TNF-α levels in this study is between
23.50±2.29 pg/ml to 68.00±13.44 pg/ml. The mean
TNF-α level is 46.90±21.9 pg/ml. The mean TNF-α
level is 39.43±5.50pg/ml for preventive treatment and
50.19±7.0 pg/ml for curative treatment. The mean TNF-
α level is 42.83±3.25 pg/ml for necropsy at week 12 and
46.79±9.33 pg/ml at week 16. TNF-α levels are
presented on Table 1.
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Analysis of variance showed that the takokak
concentration has significant effect on TNF-α levels
(p=0.000), higher takokak concentration is correlated
with greater increase in TNF-α levels. TNF-α level for
preventive treatment is lower than curative treatment.
Analysis of variance showed that preventive and
curative treatments have significant effect on TNF-α
levels (p=0.021). TNF-α level for necropsy at week 12
(42.83±3.25 pg/ml) showed lower propensity than TNF-
α level for necropsy at week 16 (46.79±9.3 pg/ml), but
the difference is not statistically significant (p=0.882).
Time of necropsy at weeks 12 and 16 has no effect on
TNF-α levels.
Interaction between takokak concentration with
increased concentration and preventive or curative
treatment has significant effect on TNF-α levels
(p=0.011), increased takokak concentration and
preventive or curative treatment play a role in the
increase of TNF-α levels.
IL-6 Levels
The range of IL-6 levels is between 9.34±0.1 pg/ml
to 21.81±0.40 pg/ml. The mean IL-6 level is 16.62±6.3
pg/ml. The mean IL-6 level is 16.82±6.4 pg/ml for
preventive treatment and 16.43±6.2 pg/ml for curative
treatment. The mean IL-6 level is 16.50±6.2 pg/ml for
necropsy at week 12 and 16.56±7.5 pg/ml at week 16.
The IL-6 levels are presented on Table 2.
Analysis of variance showed that different takokak
concentration has significant effect on IL-6 levels
(p=0.000), higher takokak concentration is correlated
with lower IL-6 levels. Takokak is assumed to have
such effect because it contains alkaloid, triterpenoid and
tannin that can counteract free radicals and thus
suppressing inflammation. Preventive and curative
treatment has no effect on IL-6 levels (p=0.265),
preventive and curative treatments did not cause a
difference in IL-6 levels. Time of necropsy (weeks 12
and 16) has no effect on IL-6 levels (p=0.904).
Interaction between takokak concentration with
different concentration and preventive or curative
treatments has significant effect on IL-6 levels
(p=0.000), higher takokak concentration and preventive
or curative treatment play a role in the decrease of IL-6
levels.
Superoxide Dismutase (SOD) Levels
The range of SOD level is between 4.37±0.20 µ/ml
to 7.96±1.10µ/ml. The mean overall SOD level is
5.93±2.30 µ/ml. The mean SOD level is 5.95±2.3µ/ml
for preventive treatment and 5.90±2.2µ/ml for curative
treatment. The mean SOD level is 6.55±2.3µ/ml
necropsy at week 12 and 5.31±1.9 µ/ml at week 16.
Analysis of variance showed that takokak
concentration has significant effect on SOD levels
(p=0.023), higher takokak concentration is correlated
with higher SOD levels. Preventive and curative
treatments have no effect on SOD levels (p=0.480),
preventive treatment showed higher SOD levels than
curative treatment. Time of necropsy (weeks 12 and 16)
has significant effect on SOD levels (p=0.000),
necropsy at week 12 showed higher SOD levels than
necropsy at week 16.
Interactions between takokak concentration and
preventive or curative treatment have significant effect
on SOD levels (p=0.012), concentration of takokak
given as preventive or curative treatments play a role in
the increase of SOD levels. Interaction between takokak
concentration, preventive or curative treatments and
time of necropsy (weeks 12 and 16) have significant
effect on SOD levels (p=0.010), higher takokak
concentration and preventive or curative treatment and
time of necropsy at week 12 and 16 play a role in the
increase of SOD levels. The SOD levels are presented
on Table 3.
DISCUSSION
Body Weight
The fodder consumed by rats has caused a
significant increase in body weight every week, this
suggests that the fodder consumed was adequate
because it can cause weight gain. The administration of
takokak with higher concentration as preventive or
curative treatments can cause weight gain. However,
weight gain for preventive treatment is higher than
curative treatment. Preventive treatment group showed
propensity to have more weight gain for higher takokak
concentration, whereas the curative group showed
propensity to have lower body weight for higher
takokak concentration. This might be explained by less
number of rats with cancer in the preventive treatment
group, and more rats with cancer in the curative
treatment group. Cancer might influence the appetite,
thus rats on curative treatment group have a tendency to
show a decrease in body weight.
TNF-α
Cytokine is a substance that can facilitate cancer
growth, invasion and metastasis by causing DNA
damage and inhibiting DNA repair through RO (reactive
oxygen), and also by deactivating tumor suppressor
gene.13 TNF-α is a cytokine that plays a role in
inflammation, immunity, cellular homeostasis and
tumor progression.14 Takokak extract can increase TNF-
α levels. Takokak is assumed to have such effect
because the extract contains certain phytochemicals
components such as alkaloid, tannin, triterpenoid and
solasodin and solamargin, which have the ability to
increase pro-apoptotic protein or inhibit anti-apoptotic
protein that may reduce inflammation. Higher takokak
extract administration is correlated with more cancer
cell death thus reducing the inflammation. The result of
the current study is different with the research from
Hanaa et al,15 where red sea soft coral (mixture of
Saecophyton trocheliophorum, Sinularia polydactyla,
Xenia macrospiculata) methanol extract can decrease
the TNF-α levels on rats fed with DMBA (10 μg/rat in
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0.2 ml acetone) and 10 µg TPA (Topical Tumor
Promoter) in 0.2 ml acetone intraperitoneal.
IL-6 Levels
IL-6 is a pro-inflammatory cytokine produced by T
cells and macrophages to stimulate immune response
during infection or tissue damage.16 Based on a study by
Rinco, IL-6 also plays a role in several diseases such as
cancer, neurological disease and metabolic syndrome.
The increase of IL-6 level in tumor cells is correlated
with cancer growth. IL-6 is also a target for cancer
therapy.17 Up-regulated cytokine (IL-6) levels in
inflammation can have an impact on cancer cells.
Several cancers with metastasis showed an increase in
IL-6 levels. Some cancer cells can stimulate the
surrounding stromal cells (connective tissue) to produce
a number of cytokines.18 IL-6 blocking may be of
benefit for several diseases.19 The results of this study
showed that takokak extract administration may
significantly reduce IL-6 levels, presumably because
takokak extract contains several phytochemicals that
can counteract free radicals. Reduction in radical
compounds will cause the body reaction to produce less
IL-6. Preventive takokak extract administration group
(takokak extract was administered together with
DMBA) showed lower IL-6 levels compared to curative
group (takokak extract was administered after DMBA)
during necropsy at week 12, and this finding showed
that preventive takokak extract administration may
improve IL-6 levels. On the contrary, preventive
takokak extract administration during necropsy at week
16 did not improve IL-6 levels, possibly because the rats
already had more advance inflammation during
necropsy at week 16, hence takokak extract cannot
suppress inflammation. This results showed similarities
with Alkaladi20 where Silymarine administration
(flavonoid extracted from Silybum marianum) can
decrease the levels of IL-6.
IL-6 also plays a role in several diseases such as
cancer, neurological disease and metabolic syndrome.
The results showed that chronic inflammation may lead
to an increase in cancer risk, promoting tumor
progression, and promoting metastasis. In the early
stage of tumor progression, inflammatory mediators
such as cytokine, ROS and RNS is derivative of tumor-
infiltrating immune cells.21
SOD Levels
Superoxide dismutase (SOD) is an enzyme (co-
factor protein) that catalyzes the reaction with
superoxide (O2-) into oxygen and hydrogen peroxide.
Intracellular SOD is the first substance to fight ROS
(reactive oxygen species).22 Antioxidant works through
3 different mechanism: 1). Prevention. Preventive
antioxidants attempt to stop the formation of ROS.
These include superoxide dismutase (SOD) that
catalyzes the dismutation of superoxide (O2-) to H2O2
and catalase that breaks it down to H2O; 2).
Interception. Interception of free radicals is mainly by
radical scavenging of peroxyl radicals, such as vitamins
C and E, glutathione, flavonoids, polyphenol, etc.; 3).
Repair and reconstitution, mainly by influencing
enzymes involved in free radicals.23 SOD is an
antioxidant enzyme with the ability to suppress
proliferation and have an effect on inflammation.
Inflammation-induced cancer can be explained by the
activation of immune cells and cytokine by oxidative
stress from free radicals.24
Takokak extract administration can increase the
SOD levels. Preventive and curative administration of
takokak extract and time of necropsy at weeks 12 and
16 is correlated with the increase of SOD levels. This
effect is attained because takokak extract contains
phenol (antioxidant) which known to be able to stop
ROS production, counteract free radicals and influence
several enzymes related to free radicals. Increased SOD
level, an antioxidant enzyme, may counteract free
radical compounds, and with the decrease in free radical
compounds, the body will produce less pro-
inflammatory protein such as IL-6. This results were in
line with Paliwal,25 in which the administration of 200-
400 mg/kgBW Moringa oleifera (moringa leaves)
ethanol-water extract was able to increase the SOD
levels on mice fed with 15 mg/kgBW DMBA for 15
days.
CONCLUSIONS
Takokak concentration has significant effect on the
increase of TNF-α and SOD levels,  and the decrease of
IL-6 levels.
RECOMMENDATION
Takokak extract at a dose of 800 mg/kgBW can be
used to prevent inflammation.
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Table 1. TNF-α levels of the rats during the study
Extract
concentration
mg/kg
Time of necropsy
Week
Mean
Mean
12 16
Preventive Curative Preventive Curative Preventive Curative
(pg/ml)
0 26,50±0,0 28,33 ±1,6 23,50±2,2 28,67±3,0 24,70±10C 28,50±9,1CB 26,3±10,5c
400 30,00 ±0,7 62,33±6,6 44,25±11,6 54,00±9,1 37,12±22B 59,00±20A 49,3±22,2b
800 44,33±5,2 65,50±5,2 68,00±13,4 62,33±16,3 66,50±24A 63,91±23 A 65,1±25,2a
Mean 33,61±2,0 52,06±4,5 45,25±9,1 48,33±9,5 39,43±5,5b 50,19±7,0a 46,9±21,9
v
a
l
u
e
Kt 0,000*
Pn 0,021*
N 0,882
Kt*pn 0,011*
Kt*N 0,827
Pn*N 0,165
Kt*pn*N 0,216
Description:
Kt: Takokak concentration
Pn: Handling
N: Necropsy
Kt*pn : Interaction between takokak concentration and handling
*: significant
Uppercase notation showed interaction
Figure 1. Rats body weight in the preventive group. Figure 2. Rats body weight in the curative group.
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Table 2. IL-6 levels of the rats during the study
Extract
Concentration
mg/kg
Time of necropsy
Week
Mean
Mean
12 16
Preventive Curative Preventive Curative Preventive Curative
(pg/ml)
16,71± 0,5 18,71 ±0,8 17,14±0,5 19,57±1,4 16,96±6,5B 19,26±6,5A 18,11±6,6a
400 20,21±0,0 15,07±0,7 18,01±3,8 14,21±0,1 19,10±7,3A 14,72±6,1C 16,91±6,7b
800 9,34 ±0,1 14,71±0,4 21,81±0,4 15,91±0,1 14,38±5,3C 15,28±6,0C 14,83±5,7c
Mean 15,42±0,2 16,16±0,6 18,98±1,5 16,56 ±0,5 116,82±6,4a 16,43 ±6,2a 16,62±6,3
p
v
a
l
u
e
Kt 0,000*
Pn 0,265
N 0,904
Kt*pn 0,000*
Kt*N 0,052
Pn*N 0,265
Kt*pn*N 0,899
Kt: Takokak concentration
Pn: Handling
N: Necropsy
Kt*pn : Interaction between takokak concentration and handling
*: significant
Table 3. SOD levels of the rats during the study
Extract
concentration
mg/kg
Time of Necropsy
Week
Mean
Mean
12 16
Preventive Curative Preventive Curative Preventive Curative
(μ/ml)
0 7,96±1,1 A 6,07±0,4CD 5,34±0,3CDE 4,90±0,3DE 6,38±2,4AB 5,48±1,9B 5,89±2,3ab
400 5,23±1,2CDE 6,42±0,8BC 5,66±0,5CDE 4,37±0,2E 5,48±2,0B 5,60±2,1B 5,54±2,1b
800 6,33±0,1BC 7,46±1,1AB 5,51±0,1CDE 5,79±0,3CD 6,00±2,5AB 6,62±2,5A 6,34±2,5a
Mean 6,50±0,8 6,65±0,8 5,50 ±0,3 5,02±0,3 5,95±2,3a 5,92±2,2a 5,93±2,3
p
v
a
l
u
e
Kt 0,023*
Pn 0,480
N 0,000*
Kt*pn 0,012*
Kt*N 0,197
Pn*N 0,199
Kt*pn*N 0,010*
Kt: Takokak concentration
Pn: Handling
N: Necropsy
Kt*pn : Interaction between takokak concentration and handling
*: significant
Synopsis:
Takokak (Solanum torvum) ethanol extract plays a role
in reducing inflammation, have significant effect in
reducing the IL-6 levels and increasing the TNF-α and
SOD levels.
REFERENCES
1. Parmar J, Sharma P, Verma P, Goyal.
Chemopreventive action of Syzygiumcumini
on DMBA-induced skin papillomagenesis in
mice. Asian Pacific J Cancer Prev. 2010;11:
261-265.
2. Haitian L, Ouyang W,  Chuanshu H.
Inflammation, a keyevent in cancer
development. Molcancer Res. 2008;4:221-233.
3. Chatterje M, M. Janarthana, R. Manivannana,
Ranab A. Gene expression and histopathology
alterations during rat mammary carcinogenesis
induced by 7,12- dimethylbenz[a]anthracene
and the protective role of Neem
Journal of Biomedicine and Translational Research 01(2015) 7 - 15
14
(Azadirachtaindica) leaf extract. Journal of
American Science.2010.
4. Alakilli  SYM. Gene expression and
histopathology alterations during rat mammary
carcinogenesis induced by 7,12-
dimethylbenz[a]anthracene and the protective
role of Neem (Azadirachtaindica) leaf extract.
Journal of American Science.2010;6(9):261-
275.
5. Manoharan S, Kavitha K, Senthil N,
RenjuGL. Evaluation of  anti-carcinogenic
effects of Clerodendroninermeon7,12-
dimethylbenz(a)anthracene induced hamster
bucca lpouch carcinogenesis. Singapore
med J.2006;12:1038.
6. Bellik Y, Boukraâ L, Alzahrani HA,
Bakhotmah BA, AbdellahF, Hammoudi,
Ouada  M. Molecular mechanism underlying
anti-inflammatory and anti-allergic activities of
phytochemicals. Molecules.2013;18: 322-353.
7. Amir M, Kumar S. Possible industrial
applications of genus Solanum in twenty first
century. Journal of Scientific aand Industrial
Research .2004;63:116-124.
8. Herlina E.Toksik dan hepatologi dan
biotransformasi senyawa toksik lamtoro merah
(Acacia villosa) pada tikus [disertasi].Sekolah
Pascasarjana Institut Pertanian
Bogor.14.Balkwill F, Mantovani A. 2001.
Inflammation and cancer: back to Virchow
Lancet. 2007;45: 357: 539.
9. Jun M, Yamashita N, Morino T, Tanaka M,
Kobayashi T, Honda H. Hyperthermic
treatment of DMBA-induced rat mammary
cancer using magnetic
nanoparticles.BioMagnetic Research and
Technology.2008;6:2.
10. Nadi M, Mosaffa N, Karimi F,  Kamalinejad
M, Farrokhi B, Anissian A, Pakzad.Iranian
black tea and cowslip extracts induce tumor
necrosis factor-alpha secretion from mouse
macrophage cell culture. Iranian Journal of
Pharmaceutical Research.2010; 1: 83-87.
11. Laosim T, Chuchawanku S, Tencomnao T.
Immunomodulatory effect of hexane extract of
Vernoniacinerea Less. trunk on human
peripheral blood mononuclear cells. Journal of
Chemical and Pharmaceutical
Research.2011;3:188-195.
12. Mahmood  NA. Oxidative stress and
antioxidant status in colorectal    Cancer and
Healthy Subject.Cancer and Medical
Genetics.2010;3:1-6.
13. Balkwill F, Mantovani A. Inflammation and
cancer: back to Virchow Lancet. 2001;45: 357:
539.
14. Zhou,  Wu. TNF-a/NF-kB/Snail pathway in
cancer cell migration and invasion. British
Journal of Cancer.2010;102: 639-644.
15. HanaaHA, Fathia M, Selim FE. Modulatory
effect of the red sea softcoral extracts on
hepatotoxicity inducedby carcinogenic agents
in rat model.J. Egypt. Soc. Toxicol.35: 97-
10717. Simpson RJ, Hammacher A, Smith DK,
Mati’hews JN, Ward LD. 1997.   Interleukin-6:
Structure-function  relationships. Protein
Science.2006;6929-955.
16. Simpson RJ, Hammacher A, Smith DK,
Mati’hews JN, Ward LD. Interleukin-6:
Structure-function  relationships. Protein
Science. 1997;6929-955.
17. Rincon M.. Editorial special issue on
interleukin-6 (IL-6) Int. J. Biol. Sci.
2012;8:1225-1226.
18. Tawara K, Oxford JT, Cheryl L Jorcyk Clinical
significance of interleukin (IL)-6 in cancer
metastasis to bone: potential of anti-IL-6
therapies Cancer Management and Research
Dovepress. Cancer Management and Research
Dovepress.2011;3:177–189.
19. Trikha M, Corringham R, Klein B, Franc J,
Corringham R. Targeted anti-interleukin-6
monoclonalantibodytherapy for cancer: A
Review of the Rationale and Clinical Evidence.
Clinical Cancer Research. 2003.9:4653–4665.
20. Alkaladi A, Abdelazim AM. Improved anti-
Inflammatory effect of Silymarin in rats
induced liver carcinogenesis. World Applied
Sciences Journal.  2013.2:176-180.
21. Multhoff G, Molls M, Radons J. Chronic
inflammation in cancer development.Front.
Immunol.doi: 2012;10.3389.
22. Otitoju O, Onwurah INE, Otitoju GTO, Ugwu
CE. Oxidative stress and superoxide dismutase
activity in brain of rats fed with diet containing
permethrin. Biokemistri. 2008; 20(2):93-98.
23. Devasagayam TPA, Tilak, JC, Boloor KK,
Sane KS, Ghaskadbi SS, Lele RD. Free
radicals and antioxidants in human
health:Current status and future prospects. J
Assoc Physicians India. 2004;52:794-804.
Journal of Biomedicine and Translational Research 01(2015) 7 - 15
15
24. Mahmood  NA. Oxidative stress and
antioxidantstatus in colorectal    Cancer and
Healthy Subject.Cancer and Medical
Genetics.2010;3:1-6.
25. Paliwal R,Sharma V, Pracheta, Sharma S,
Yadav S, Sharma S. Anti-nephrotoxic effect of
administration of Moringaoleifera Lam in
amelioration of DMBA-induced renal
carcinogenesis in swiss albino mice.Biology
and Medicine.22011:27-35.
